GlassScriptPhysician profile
Paul D Rothwell
NPI 1306818984
$4,079.50
in general payments reported to CMS, 2019-2025
43 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $167 · 2021: $546 · 2022: $853 · 2023: $899 · 2024: $801 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.04 | 2021-2024 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $424.57 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $392.13 | 2019-2025 | |
| Lilly USA, LLC | $388.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $382.25 | 2022-2024 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $297.47 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $243.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.87 | 2019 | |
| Astellas Pharma US INC | $118.89 | 2019-2025 | Veozah |
| Dexcom, INC. | $115.36 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $107.18 | 2021-2025 | |
| Medtronic, INC. | $65.55 | 2023-2024 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $62.25 | 2022-2023 | Trintellix |
| Amgen INC. | $55.25 | 2021-2023 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $54.91 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rothwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.